Category: Uncategorized

Recognition from U.S. regulatory authorities On January 19, 2026, the U.S. Food and Drug Administration (FDA) officially granted "Breakthrough Therapy"... Read more

Signals of a capital market recovery The beginning of 2026 has witnessed signs of a resurgence in the biotech IPO... Read more

Consolidation of global control On January 19, 2026, AstraZeneca officially reached an agreement to acquire AbelZeta Pharma’s 50% stake in... Read more

Executive leadership transition On January 16, 2026, Emmecell, a clinical-stage biotechnology company pioneering magnetic cell delivery (MCD) technology, officially appointed... Read more

Extension of strategic partnership Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has officially extended its long-standing... Read more

Collaboration between pharmaceutical industry leaders On January 19, 2026, SCHOTT Pharma (a specialist in drug containment) and SHL Medical (a... Read more

Consolidation of global control AstraZeneca has officially reached an agreement to acquire AbelZeta Pharma’s 50% stake in the development and... Read more

Completion of equity acquisition Harbour BioMed has announced that its wholly owned subsidiary exercised a warrant agreement to acquire common... Read more

Large-scale product portfolio update On January 19, 2026, Qosina officially released its "New Product Preview," showcasing more than 500 newly... Read more